14 week, Phase 4, Open Label, Decentralized Study finds that Viloxazine ER reduced ADHD symptoms by 45.3% in adults with comorbid depression/anxiety. 71.8% achieved ≥30% symptom reduction. Depression
Next post
Tungsten may suffer more radiation damage in fusion reactors than expected
